Zepbound

Zepbound

Purpose: A once-weekly injectable medication prescribed for adults managing obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with related health conditions, and for weight-associated moderate-to-severe obstructive sleep apnea (OSA). It must be used with a reduced-calorie diet and increased physical activity.

How It Works: It activates two hormone receptors—GLP‑1 and GIP—to reduce appetite, slow digestion, and enhance fullness, potentially leading to substantial weight loss.

Dosage & Administration

Start & Maintenance

• Begin with 2.5 mg once weekly for 4 weeks.
• Increase by 2.5 mg every 4 weeks, as tolerated, up to a maximum of 15 mg weekly.
  • Weight loss maintenance: 5 mg, 10 mg, or 15 mg.
  • OSA management: 10 mg or 15 mg.

Missed Dose

• If missed, take within 4 days (96 hours); otherwise, skip and resume the usual schedule.
• To shift your dosing day, ensure at least 3 days (72 hours) between injections.

 Injection Technique

(See visuals above for step-by-step guidance)

• Choose your injection site: abdomen, thigh, or upper arm. Rotate sites each week.
• Using the pen:
  1. Pull off cap.
  2. Place and unlock the pen against skin.
  3. Press and hold for up to 10 seconds. Listen for two clicks—this confirms full dose delivery even if you don’t feel anything.
• Using vials (if pen unavailable): Follow steps like swabbing, drawing the dose with a syringe, ejecting air bubbles, and injecting subcutaneously, as shown in the images.

Important Safety Information

Contraindications

• Do not use if you or your family have a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Warnings & Common Side Effects

• In animal studies (rats), Zepbound caused thyroid C‑cell tumors; human relevance is unknown. Report symptoms like neck lumps, hoarseness, difficulty swallowing, or shortness of breath.
• May lead to gastrointestinal issues—nausea, vomiting, diarrhea—or dehydration that could harm the kidneys. Stay well-hydrated.
• Other possible effects: gallbladder disease, pancreatitis, serious allergic reactions (e.g. swelling, rash, breathing difficulties), and low blood sugar if on other medications like insulin or sulfonylureas.
• The most common adverse reactions reported in ≥5% of patients treated with Zepbound are nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, and gastroesophageal reflux disease.
• Oral contraceptives may be less effective when starting or increasing dose—use non-oral or barrier methods for 4 weeks after each change.

Storage & Handling

• Keep refrigerated (36‑46 °F / 2‑8 °C) in its original packaging to protect from light.
• Can be kept at room temperature (up to 86 °F / 30 °C) for up to 21 days—discard if unused beyond that.
• Always inspect before use—the solution should be clear and colorless to slightly yellow. Do not use if discolored or contains particles.

Quick Reference Table